Parkinsonism & related disorders最新文献

{"title":"Boostering motor imagery processing to improve gait in patients with Parkinson disease and freezing of gait: A pilot study","authors":"Susanna Mezzarobba ,&nbsp;Elisa Ravizzotti ,&nbsp;Paolo Bernardis ,&nbsp;Martina Putzolu ,&nbsp;Carola Cosentino ,&nbsp;Alessandro Botta ,&nbsp;Gaia Bonassi ,&nbsp;Roberta Marchese ,&nbsp;Sara Terranova ,&nbsp;Giovanna Lagravinese ,&nbsp;Laura Avanzino ,&nbsp;Elisa Pelosin","doi":"10.1016/j.parkreldis.2024.107173","DOIUrl":"10.1016/j.parkreldis.2024.107173","url":null,"abstract":"<div><h3>Background</h3><div>Given that patients with Parkinson's Disease (PD) and Freezing of Gait (FoG) may lack the cognitive resources necessary to activate the motor imagery (MI) process, investigating how to boost MI vividness and accuracy could be a valuable therapeutic strategy in MI Practice (MIP).</div></div><div><h3>Objective</h3><div>We aim to evaluate the priming effect of visual, or auditory, or attentional stimuli in enhancing MI ability by using quantitative data on gait and turning performance.</div></div><div><h3>Methods</h3><div>Nineteen PD participants with FoG underwent four one-week sessions of MIP, with pre and post clinical assessments. Each session included MI alone or one of three booster MI tasks (Attentional, Action observation, or Auditory) before imagining and executing walking straight and performing a 180° turn. Gait and turning performances were evaluated using six inertial sensors before and after each session.</div></div><div><h3>Results</h3><div>Our findings showed that both MI and boosted MI induced similar improvement in gait (speed and stride length) and 180° (step number and velocity) and 360° turning (velocity, angle) parameters compared to baseline. When differences among “booster” tasks were analyzed, results showed that Auditory and Attentional boosted MI were superior to MI alone in some gait and turning parameters. At the end of the 4 sessions, MI ability measured by means of Kinesthetic and Visual Imagery Questionnaire and Gait Imagery Questionnaire and FoG symptoms were also improved.</div></div><div><h3>Conclusion</h3><div>Our preliminary results suggest that boosting MI is a feasible strategy for enhancing MI ability and addressing FoG symptoms. Auditory and Attentional conditions appear to enhance the priming effect of MI on gait and turning performance more effectively.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"129 ","pages":"Article 107173"},"PeriodicalIF":3.1,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142472290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: Cognitive and morphometric features of mild cognitive impairment reversion in early patients with Parkinson's disease.","authors":"Kazuya Kawabata, Werner Poewe","doi":"10.1016/j.parkreldis.2024.107163","DOIUrl":"https://doi.org/10.1016/j.parkreldis.2024.107163","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":" ","pages":"107163"},"PeriodicalIF":3.1,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142472289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in progressive supranuclear palsy in patients of Asian ancestry?","authors":"Shen-Yang Lim, Azalea T Pajo, Alfand Marl F Dy Closas, JiaWei Hor, Tzi Shin Toh, Su Juen Ngim, Yi Zhe Lim, Ai Huey Tan","doi":"10.1016/j.parkreldis.2024.107162","DOIUrl":"https://doi.org/10.1016/j.parkreldis.2024.107162","url":null,"abstract":"<p><p>Recent studies highlight an over-representation of progressive supranuclear palsy, with atypical features, in South Asians. We offer additional insights, including an over-representation of PSP among Malaysian patients of Indian compared to other Asian ancestries. However, RBD symptoms, hallucinations, and early onset were not more frequent in Indians vs. Chinese.</p>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":" ","pages":"107162"},"PeriodicalIF":3.1,"publicationDate":"2024-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142472287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult-onset cranio-cervical segmental dystonia due to ADAR1 gene mutation: A novel phenotype","authors":"Rohan Mahale,&nbsp;Gautham Arunachal,&nbsp;Hansashree Padmanabha,&nbsp;Pooja Mailankody","doi":"10.1016/j.parkreldis.2024.107160","DOIUrl":"10.1016/j.parkreldis.2024.107160","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"129 ","pages":"Article 107160"},"PeriodicalIF":3.1,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in fatigue of Parkinson's disease during the recurrent COVID‐19 pandemic: Findings from the longitudinal analysis of the PHASE study","authors":"Hiroshi Kataoka ,&nbsp;Keigo Saeki ,&nbsp;Yoshiaki Tai ,&nbsp;Hitoki Nanaura ,&nbsp;Takao Kiriyama ,&nbsp;Kazuma Sugie ,&nbsp;Kenji Obayashi","doi":"10.1016/j.parkreldis.2024.107161","DOIUrl":"10.1016/j.parkreldis.2024.107161","url":null,"abstract":"<div><h3>Background</h3><div>According to Japanese law, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the COVID-19 pandemic falls under Category 2, implying that it necessitates hospitalization, isolation, and significant government participation. The category of infection was lowered to Category 5 in May 2023, meaning that individuals were going back to live their lives as they did before the COVID-19 pandemic.</div><div>This study aimed to explore changes in the prevalence of non-motor symptoms over a longer four-year period, spanning before and after the COVID-19 pandemic.</div></div><div><h3>Methods</h3><div>We conducted a questionnaire survey between January and February in the following years: 2021, 2022, 2023, and 2024.</div></div><div><h3>Results</h3><div>The Parkinson's fatigue scale score in 2021 (mean: 35.3) increased significantly in 2022 (49.84), 2023 (49.33), and 2024 (54.71) (p &lt; 0.001). After adjusting for baseline score using a mixed linear model with random intercept, the Parkinson's fatigue scale was significantly increased by 15.9 points (95 % CI: 10.9 to 20.9) in 2022, 13.1 points (7.9–18.3) in 2023, and 16.9 points (11.3–22.6) in 2024 independently of all potential confounders including other non-motor symptoms.</div></div><div><h3>Conclusions</h3><div>The four years of longitudinal observation during the recurrent COVID-19 pandemic revealed that patients with PD experienced an increase in fatigue. Now, post-COVID-19 fatigue is attracting attention; however, the severity of fatigue may have already deteriorated during the period of recurrent COVID-19 pandemic.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"129 ","pages":"Article 107161"},"PeriodicalIF":3.1,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monocyte to high-density lipoprotein cholesterol ratio reflects the peripheral inflammatory state in parkinsonian disorders","authors":"In Hee Kwak ,&nbsp;Young Eun Kim ,&nbsp;Yun Joong Kim ,&nbsp;Hye-Mi Noh ,&nbsp;Jeongjae Lee ,&nbsp;Je Kook Yu ,&nbsp;Hyeo-il Ma","doi":"10.1016/j.parkreldis.2024.107155","DOIUrl":"10.1016/j.parkreldis.2024.107155","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;In Parkinson’s disease (PD) and Parkinson plus syndrome (PPS), inflammation is recognized as a relevant or contributing factor in the advancement of the diseases. For this reason, numerous biomarkers signaling immune alteration in both the central and peripheral nervous systems have been evaluated in PD and PPS. Nonetheless, the comprehensive inflammatory indices derived from readily available standard blood tests in PD, PPS, and healthy controls (HC) were rarely evaluated especially in the early stage of the diseases.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;The aim of this study is to explore the serum level of peripheral inflammatory markers among the patients and investigate whether these markers contribute to symptoms.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Method&lt;/h3&gt;&lt;div&gt;Clinical data and blood test results from drug naïve, early-stage 139 PD and 87 PPS patients, along with 139 age- and sex-matched healthy controls (HC) to PD were enrolled, with exclusion criteria applied to conditions potentially affecting inflammation. The study examined the disparities in peripheral inflammation among the groups, using total and subpopulation of white blood cells (WBCs), platelet count, red cell distribution width (RDW), high-density lipoprotein cholesterol (HDL-C), and other composite values reflecting inflammation including RDW to platelet ratio (RPR), neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), platelet to lymphocyte ratio (PLR), neutrophil to HDL-C ratio (NHR), monocyte to HDL-C ratio (MHR), lymphocyte to HDL-C ratio (LHR), platelet to HDL-C ratio (PHR), systemic inflammation index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Result&lt;/h3&gt;&lt;div&gt;The MHR values were significantly higher in both PD and PPS groups compared to HC (&lt;em&gt;p &lt; 0.001&lt;/em&gt;), and NHR was significantly higher in the PPS group only compared to the HC group (&lt;em&gt;p &lt; 0.001&lt;/em&gt;). However, no significant differences in all the inflammatory markers were observed between PPS and PD (&lt;em&gt;p &gt; 0.05&lt;/em&gt;). Subgroup analysis of progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) patients revealed significantly higher NHR and MHR levels compared to the HC group (&lt;em&gt;p&lt;/em&gt; = &lt;em&gt;0.025, p&lt;/em&gt; = &lt;em&gt;0.050, respectively&lt;/em&gt;), with no significant difference among PSP, MSA, and PD groups. After adjustment for age, sex, and disease duration, MHR was positively associated with H&amp;Y in the total population (β = 0.288, p &lt; 0.001), negatively associated with MMSE in the PD group (β = −0.245, p = 0.017), and positively associated with both H&amp;Y (β = 0.432, &lt;em&gt;p &lt; 0.001&lt;/em&gt;) and UPDRS part II (β = 0.295, &lt;em&gt;p&lt;/em&gt; = &lt;em&gt;0.018&lt;/em&gt;) in PPS group.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;NHR and MHR values are not effective as reliable diagnostic markers due to overlap among groups and their limited discriminative capacity in ROC analyses. However, ","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"129 ","pages":"Article 107155"},"PeriodicalIF":3.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142446412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new genetic variant, presenting as young onset rapidly progressive dementia and parkinsonism","authors":"","doi":"10.1016/j.parkreldis.2023.105849","DOIUrl":"10.1016/j.parkreldis.2023.105849","url":null,"abstract":"<div><div><span><span><span>There are various neurodegenerative or hereditary causes of Parkinsonism. Therefore, clinicians should consider an increasing range of </span>differential diagnoses<span> when facing a patient with Parkinsonism, especially when associated with additional </span></span>clinical features<span>. Young-onset Parkinsonism, especially when accompanied by features uncommon in idiopathic </span></span>Parkinson's disease<span> raises the possibility of genetic etiology.</span></div><div>Herein, we present a case of a 40-year-old man with genetic Parkinson's disease, presenting with rapidly progressive dementia. This round will describe our approach to this clinical presentation and the unveiling of a rare genetic condition.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"127 ","pages":"Article 105849"},"PeriodicalIF":3.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41133736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert Commentary: A new genetic variant, presenting as young onset rapidly progressive dementia and parkinsonism","authors":"","doi":"10.1016/j.parkreldis.2024.106946","DOIUrl":"10.1016/j.parkreldis.2024.106946","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"127 ","pages":"Article 106946"},"PeriodicalIF":3.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140274477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prospective role of mesenchymal stem cells in Parkinson's disease","authors":"Pratima Tambe ,&nbsp;Vaishali Undale ,&nbsp;Avinash Sanap ,&nbsp;Ramesh Bhonde ,&nbsp;Nishant Mante","doi":"10.1016/j.parkreldis.2024.107087","DOIUrl":"10.1016/j.parkreldis.2024.107087","url":null,"abstract":"<div><div>Parkinson's disease (PD) is a stressful neurodegenerative disorder affecting millions worldwide. PD leads to debilitating motor and cognitive symptoms such as tremors, rigidity, and difficulty walking. Current therapies for PD are symptomatic and don't address the root cause. Therefore, there is an urgent need for better management and intensive research into alternative therapies. Mesenchymal stem cell (MSC) therapy is among the leading contenders among these promising avenues. We examined preclinical and clinical evidence demonstrating the neuroprotective, anti-inflammatory, and regenerative properties of the MSCs. This review focuses on the complex pathophysiological mechanisms of PD, as well as the perspectives of MSCs and their derivatives, such as secretomes and exosomes, in the clinical management of PD. We also analyzed the challenges and limitations of each approach, including delivery methods, timing of administration, and long-term safety considerations.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"127 ","pages":"Article 107087"},"PeriodicalIF":3.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between clinical and neuropathological subtypes of PSP: Do clinical symptoms reflect tau distribution?","authors":"Jee Bang,&nbsp;Alexander Pantelyat","doi":"10.1016/j.parkreldis.2024.107108","DOIUrl":"10.1016/j.parkreldis.2024.107108","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"127 ","pages":"Article 107108"},"PeriodicalIF":3.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142140775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}